Glenn Michelson

Title: Glenn Michelson: Innovator in Hematologic Disorder Treatments

Introduction

Glenn Michelson is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of medicine, particularly in the treatment of hematologic disorders. His innovative work has led to the development of methods that can potentially improve patient outcomes in this challenging area of healthcare.

Latest Patents

Glenn Michelson holds a patent for "Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders." This patent outlines methods for treating, preventing, or managing conditions such as myelodysplastic syndrome and chronic myelomonocytic leukemia. The methods involve the administration of SNS-595, which can be used in combination with various therapies, including chemotherapy and immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for these methods are also included in the patent.

Career Highlights

Glenn Michelson is associated with Sunesis Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in hematologic treatments. His work has focused on innovative approaches to combat complex blood disorders, showcasing his commitment to improving patient care.

Collaborations

Throughout his career, Glenn has collaborated with esteemed colleagues, including Daniel C. Adelman and Jeffrey A. Silverman. These partnerships have fostered a collaborative environment that enhances the development of effective treatment methodologies.

Conclusion

Glenn Michelson's contributions to the field of hematologic disorders through his innovative patent and collaborative efforts highlight his dedication to advancing medical science. His work continues to pave the way for new treatment options that can significantly impact patient lives.